MedPath

Ridaforolimus

Generic Name
Ridaforolimus
Drug Type
Small Molecule
Chemical Formula
C53H84NO14P
CAS Number
572924-54-0
Unique Ingredient Identifier
48Z35KB15K
Indication

Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.

Clinical Trials
Related News

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Phase 1
Terminated
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2010-09-30
Last Posted Date
2021-02-16
Lead Sponsor
Angela Taber MD
Target Recruit Count
12
Registration Number
NCT01212627
Locations
🇺🇸

memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States

🇺🇸

The Miriam Hospital, Providence, Rhode Island, United States

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1
Completed
Conditions
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Procedure: biopsy
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2010-07-26
Last Posted Date
2021-02-21
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
16
Registration Number
NCT01169532
Locations
🇺🇸

Fox Chase Cancer Center, Rockledge, Pennsylvania, United States

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Phase 1
Completed
Conditions
Relapsed or Refractory Advanced Cancer
Interventions
First Posted Date
2010-02-19
Last Posted Date
2015-04-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT01071304

Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

Phase 1
Completed
Conditions
Healthy Volunteers
Hepatic Insufficiency
Interventions
First Posted Date
2010-01-07
Last Posted Date
2015-04-29
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
19
Registration Number
NCT01043887

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Phase 2
Completed
Conditions
Sarcoma
Interventions
First Posted Date
2009-11-10
Last Posted Date
2015-04-30
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
50
Registration Number
NCT01010672

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Phase 1
Completed
Conditions
Metastatic or Locally Advanced Cancer
Interventions
Drug: Placebo
First Posted Date
2009-04-02
Last Posted Date
2019-05-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
23
Registration Number
NCT00874731

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Phase 2
Terminated
Conditions
Advanced Cancers
Interventions
First Posted Date
2009-02-04
Last Posted Date
2019-02-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
7
Registration Number
NCT00836927

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Phase 2
Terminated
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2009-01-08
Last Posted Date
2015-01-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
80
Registration Number
NCT00818675

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Phase 1
Completed
Conditions
Solid Tumor
Interventions
First Posted Date
2008-10-29
Last Posted Date
2015-02-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
17
Registration Number
NCT00781846

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2008-10-22
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
22
Registration Number
NCT00777959
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy